Skip to main content
Smart Investors Daily
RM

NYSE · RM

Regional Management Corp.

Financial Services · Financial - Credit Services

$38.78

Up+$0.72 (+1.86%)

Updated Nov 4, 2026, 10:59 PM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
389.54M
P/E ratio
9.82
Dividend yield
3.09%
52-week range
$29.89 – $44.30
Volume
134.08K
Avg. volume
46.76K

Price performance · RM

RM price history

1M range · 0 trading sessions · Daily adjusted prices

RM does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RM news

The latest Smart Investors Daily articles mentioning RM.

RM research

Overview

Company profile and research snapshot.

Company profile

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
RM recent ratings
DateFirmRatingTarget
Oct 29, 2026Stephens & Co.Overweight—
Jul 30, 2026CitizensMarket Outperform—
May 21, 2026CitizensMarket Outperform—
May 2, 2025Keefe, Bruyette & WoodsMarket Perform—
Nov 13, 2024Stephens & Co.Equal-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 12, 2026

Bristol Myers falls 3% despite positive cancer drug trial results

Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market’s reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.